Sfrowasa (Mesalamine) Patent Expiration, LOE Window & CMS Spending
Sfrowasa (Mesalamine) by Viatris: FDA Orange Book core substance LOE 2027-07-24, 4 AB generics, $241K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Viatris |
| FDA Application & Pathway | N019618 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-07-24 |
| Last Listed Patent or Exclusivity Date | 2027-07-24 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $241K |
| 2024 Medicare Part D Spend | $32K |
| 2024 Medicaid Spend | $209K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.